PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Imec

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

EpiGaN Raises Capital for GaN-on-Si Production - Capricorn Cleantech Fund, Robert Bosch Venture Capital (RBVC), and LRM jointly invested € 4 million in EpiGaN, spin-off of imec, to launch volume production of GaN on-silicon wafers
EpiGaN Raises Capital for GaN-on-Si Production


NewswireToday - /newswire/ - Hasselt, Belgium, 2011/07/05 - Capricorn Cleantech Fund, Robert Bosch Venture Capital (RBVC), and LRM jointly invested € 4 million in EpiGaN, spin-off of imec, to launch volume production of GaN on-silicon wafers.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


EpiGaN is pleased to announce that it has closed its first capital round of € 4 million, which will allow it to start volume production of GaN-on-Si epitaxial material for the nextgeneration efficient power electronics.

Incorporated in 2010, EpiGaN was founded by Dr Marianne Germain, CEO, Dr Joff Derluyn, CTO and Dr Stefan Degroote, COO, as a spin-off of imec. For more than 10 years, the founders jointly developed state-of-the-art GaN-on-Si technology on 4” and 6” wafers at imec, part of which has been licensed to EpiGaN. They are today joined by a strong consortium of investors who share their vision on GaN-on-Si as a key technology for enhancing power management efficiency, implementing renewable energy sources, or enabling cleaner transportation technologies with reduced environmental impact.

“EpiGaN has demonstrated the capability of its innovative material to support record device performance either in high voltage, high current or high frequency operation“, says Dr Marianne Germain, CEO of EpiGaN “we are proud that investors have decided to support our initiative and will enable us to commercially provide the same high-standards material quality in large volume to our industrial customers.”

The participation of Robert Bosch Venture Capital lends credibility to the strategic vision of the company: “We are impressed by the technological achievements of EpiGaN and the capabilities of the team. As a leading manufacturer of power electronics modules and systems, we believe that this technology has the potential to make significant contributions to the world of power conversion and are happy to be part of the investor syndicate supporting the company,” said Gadi Toren, venture capital investment partner at RBVC and future board member of EpiGaN.

Marc Lambrechts, who will join the board of EpiGaN on behalf of Capricorn Cleantech Fund, is convinced EpiGaN addresses a key target market: “Power conversion is an essential technology for an impressive number of cleantech applications such as energy efficient power supplies, solar inverters, wind energy, electric or hybrid vehicles and smart grids. The customers of EpiGaN will benefit from higher efficiency, improved reliability and reduced system size and weight, by using the EpiGaN state-of-the-art GaN-on-silicon technology.”

The support of the investors will allow EpiGaN to implement its own production capacity and increase its market supply: 4” and 6” GaN-on-Si wafers for high voltage or RF applications are readily available from EpiGaN while a 200 mm wafer technology is under development in EpiGaN. EpiGaN will deploy its activities at the Research Campus Hasselt in Limburg, geographically located squarely within Leuven, Eindhoven and Aachen.

“EpiGaN has chosen Limburg as the best location to grow their business after an in depth location study. We are happy that our intertwined offer of venture capital and sector specific infrastructure played a key role in the decision process”, says Stijn Bijnens, CEO of LRM; “EpiGaN will contribute to the development of high-tech solutions for the renewable energy domain, an area where Limburg is willing to play an important role”.

“imec has pioneered the use of Si substrates for GaN technology, for its cost efficiency and its bright perspective of leveraging on the silicon-based semiconductor industry. We are proud to see that a highly-innovative, long-term research project leads to the creation of a high-potential spin-off, bringing imec technology to the market”, concludes Luc Van den hove, President and CEO of imec.

About EpiGaN
EpiGaN ( has been incorporated in 2010 by Marianne Germain, Stefan Degroote and Joff Derluyn, as a spin-off of imec. It focuses on providing world-leading III-nitride epitaxial material solutions for top performance devices. EpiGaN gives device manufacturers access to a unique, proven and powerful technology to be used in key market segments such as power supplies for consumables, hybrid electric vehicles, solar inverters, RF power for base stations, smart grid.... The founders benefited from the entrepreneurial experience of SO Kwadraat (

About Capricorn Venture Partners
Capricorn Venture Partners ( is a pan-European manager of venture capital funds seeking to invest in technology based growth companies. Capricorn is investing out of its € 112 million Capricorn Cleantech Fund. The Cleantech Fund invests in European growth companies developing innovative breakthrough technologies in the fields of renewable energy and energy efficiency, water purification and re-use, biobased material conversion and biorefinery platforms, clean air, climate change, green chemistry and advanced materials, materials recovery and recycling. The investment team of Capricorn is composed of experienced investment managers with deep technology expertise and a broad industrial experience. The Capricorn Cleantech Fund benefits from investment by the European Investment Fund through the "Competitiveness and Innovation Framework Programme" of the European Union.

About Robert Bosch Venture Capital
The Bosch Group ( / is a leading global supplier of technology and services. In the areas of automotive and industrial technology, consumer goods, and building technology, some 285,000 associates generated sales of 47.3 billion euros in fiscal 2010. Each year, Bosch spends more than 3.5 billion euros for research and development, and applies for over 3,000 patents worldwide. With all its products and services, Bosch enhances the quality of life by providing solutions which are both innovative and beneficial. Robert Bosch Venture Capital GmbH invests worldwide in innovative startup companies at all stages of their development. Its investment activities focus on technology companies working in areas of business of current and future relevance for Bosch, above all automation and control, energy and environment, enabling technologies, and healthcare. Robert Bosch Venture Capital GmbH also invests in services/business models as well as new materials that are relevant to the above-mentioned areas of business.

About LRM
LRM ( is a profit-driven investor that offers entrepreneurs a unique combination of venture capital and real estate. LRM's activities contribute to the economic development and the general employment in Belgian Limburg. LRM is oriented towards all sectors and companies, from start-ups over growing SMEs to large enterprises. Today, LRM is active in five domains: ICT & Media, Life Sciences, Cleantech & Energy, SMEs & Large enterprises.

About imec
Imec performs world-leading research in nanoelectronics. Imec leverages its scientific knowledge with the innovative power of its global partnerships in ICT, healthcare and energy. Imec delivers industry-relevant technology solutions. In a unique high-tech environment, its international top talent is committed to providing the building blocks for a better life in a sustainable society. Since its origin in 1984 imec’s state-of-the art technology has lead to the creation of 35 spin-off companies.

Imec ( is headquartered in Leuven, Belgium, and has offices in Belgium, the Netherlands, Taiwan, US, China and Japan. Its staff of about 1,900 people includes more than 500 industrial residents and guest researchers. In 2010, imec's revenue (P&L) was 285 million euro.

Imec is a registered trademark for the activities of IMEC International (a legal entity set up under Belgian law as a "stichting van openbaar nut”), imec Belgium (IMEC vzw supported by the Flemish Government), imec the Netherlands (Stichting IMEC Nederland, part of Holst Centre which is supported by the Dutch Government), imec Taiwan (IMEC Taiwan Co.) and imec China (IMEC Microelectronics (Shangai) Co. Ltd.).

For more information:
Dr Marianne Germain, CEO
EpiGaN nv
Kempische Steenweg 293,
B-3500 Hasselt (Belgium)
T: +32 (0)475 77 89 45 / E: Marianne.Germain[.]

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Imec


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

EpiGaN Raises Capital for GaN-on-Si Production

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Imec | EpiGaN
Publisher Contact: Hanne Degans - 
+32 16 281 769 hanne.degans[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Imec securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Imec / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis
MDxHealth Announces Agreement with SouthGenetics for Distribution of SelectMDx in Central/South America
BD and Apax Partners Announce Closing of Joint Venture to Launch Global Respiratory Business
Exosome Diagnostics Enters Agreement with Amgen
Sartorius Stedim Biotech Launches Two Single-use Sartocon® Loop Assemblies with Integrated Polyethersulfone (PESU) Membrane
BD Expands Efforts to Combat Antimicrobial Resistance with New Automated ID/AST System

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  Intrinsic Executive Search Ltd

Visit  Demyk Lightmod Products, Inc.

  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (